Intracellular delivery to treat rare diseases
Larimar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead product candidate, nomlabofusp (previously known as CTI-1601), is currently being evaluated in a Phase 2 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar Therapeutics also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular proteins.